Bookmark

Add to MyYahoo RSS

Gilead Sciences News

News on Gilead Sciences (Ticker: GILD) continually updated from thousands of sources around the net.

1 hr ago | AmericanBankingNews.com

Gilead Sciences Receives "Strong-Buy" Rating from S&P Equity Research

's stock had its "strong-buy" rating restated by research analysts at S&P Equity Research in a report released on Tuesday. Other equities research analysts have also recently issued reports about the stock.

Comment?

Related Topix: Biotech, Startups, Medicine, Gilead Sciences, CGI Pharmaceuticals, Healthcare Industry

6 hrs ago | Seeking Alpha

ProQR Therapeutics: Competition, Distance From Clinical Trials Leads Us To Hold Off

PRQR, a biopharmaceutical firm seeking to develop RNA-based treatments for severe genetic disorders, plans to raise $75.0 million in its upcoming IPO. While the market for these products is massive, PRQR is still a tremendous distance from receiving approval for its treatments, having yet to even enter clinical trials for QR-010.

Comment?

Related Topix: Genetics, Medicine, Netherlands, World News, Marketing, Biotech, Healthcare Industry

10 hrs ago | Seeking Alpha

If Achillion's Hep C Nucleotide Isn't Best In Class, The Stock Is Worth Low Single Digits

If Achillion's nucleotide , ACH-3422, works as well or worse than Gilead's Sovaldi, there is little use for it in the market. Since May, Achillion has experienced an avalanche of selling by insiders and major holders, and no reported buying by institutions.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Hepatitis, Health, Merck , Achillion Pharmaceuticals, Pharmaceuticals

11 hrs ago | MarketNewsVideo

S&P 500 Movers: GILD, TAP

In early trading on Monday, shares of Molson Coors Brewing topped the list of the day's best performing components of the S&P 500 index, trading up 6.7%. Year to date, Molson Coors Brewing registers a 36.4% gain.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Business News, Video

15 hrs ago | Medical News

Gilead to boost price of new hepatitis c drug

Gilead Sciences says its next generation drug to combat hepatitis C, slated to launch next month, will be more expensive than $1,000-a-pill Sovaldi, in part because the new treatment will be shorter and simpler. Gilead also struck a deal with Indian generic drugmakers to sell lower-cost versions of Sovaldi in poor countries.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Startups, Gilead Sciences

Mon Sep 15, 2014

Seeking Alpha

Not Only Did I Sell Everything In My Roth IRA, But I Also Went Semi-Short

I don't think the world is going to end, just that there will be better opportunities to initiate stock positions at lower prices before year-end. My interest in the stock market as well as other financial markets started during my freshman year of college in 2010.

Comment?

Related Topix: IRA, Personal Finance, us Travel, Travel, Biotech, Startups, Medicine, Gilead Sciences, CGI Pharmaceuticals, Healthcare Industry, Energy, Kinder Morgan, Oil & Gas

SFGate

Access expands to Hepatitis C drug

Gregg Alton, executive vice president of Gilead Sciences, discusses distribution of Gilead's hepatitis C pill. looks on during a press conference in New Delhi on September 15, 2014.

Comment?

Related Topix: Hepatitis, Medicine, Health, Biotech, Healthcare Industry, Startups, Gilead Sciences, CGI Pharmaceuticals, World News, India, Apple

Business Wire

Press release distribution, EDGAR filing, XBRL, regulatory filings

Research and Markets: Global Healthcare Information Systems Market 2014-2018: Leading Vendors are Agfa Gevaert, GE Healthcare, McKesson, Philips Healthcare & Siemens Healthcare )--Research and Markets has announced the addition of the "Global Healthcare Information Systems Market 2... )--Eine der Hauptattraktionen der IBC ist die IBC Big Screen Experience, ein komplettes Programm von redaktionell gefA1 4hrten Sitzungen und bahnbrechenden ProduktvorfA1 4hrungen.

Comment?

Related Topix: Maximus, Consulting, Biotech, Medicine, Healthcare Industry

Business Journal

Gilead, pricey hepatitis C drug face Oregon government showdown

One Sovaldi's hottest battleground will get a little hotter Monday - and Gilead Sciences Inc. executives reportedly are warming to a deal. Oregon legislators, trying to hold the budget line for the Medicaid-funded Oregon Health Plan, hold a hearing today on the $1,000-a-pill hepatitis C treatment from Foster City-based Gilead .

Comment?

Related Topix: Biotech, Medicine, Oregon, Healthcare Industry, Oregon Government, Startups, Gilead Sciences, Medicaid, Health

BioSpace

Mylan Inc. Signs Agreement With Gilead Sciences, Inc. To Accelerate...

Sofosbuvir is marketed by Gilead under the brand name SovaldiA . The countries within the agreement account for more than 100 million people living with hepatitis C globally representing 54% of the total global infected population.1 Unfortunately, patients in these regions often lack access to critical and effective treatments.

Comment?

Related Topix: Biotech, Medicine, Pharmaceuticals, Mylan Laboratories, Healthcare Industry, Startups, Gilead Sciences, Dey, Hepatitis, Health

BioSpace

Gilead Sciences, Inc. Alllows Seven Indian Firms To Sell Cheaper Copies Of Hepatitis C Drug Solvadi

The maker of one of the costliest drugs in the world announced on Monday that it had struck agreements with seven Indian generic drug makers to sell lower-cost versions of its $1,000-a-pill Hepatitis C drug in poorer countries. The deals are intended to provide greater access to the medicine Sovaldi for most of the nearly 180 million infected worldwide with Hepatitis C who do not live in rich countries.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Startups, Gilead Sciences, Hepatitis, Health

The Miami Herald

Gilead to license generic version of Sovaldi

At Totally Dog's Redland campus, there's a pool where timid dogs can wade and the bolder ones can jump right in. "> At Totally Dog's Redland campus, there's a pool where timid dogs can wade and the bolder ones can jump right in.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Startups, Gilead Sciences

KAUZ

Gilead to license generic version of Sovaldi

Coney Island's historic B&B Carousell is among several vintage attractions still thrilling visitors at the famous amusement park today. Residents and tourists hunkered down in shelters and hotel conference rooms overnight as a powerful and sprawling Hurricane Odile made landfall on the southern Baja California peninsula.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Hurricane Odile, Hurricane, Weather

Reuters

Gilead licenses hepatitis C drug to Cipla, Ranbaxy, 5 others

U.S. drugmaker Gilead Sciences Inc said on Monday it has licensed its hepatitis C drug to seven companies including Cipla Ltd and Ranbaxy Laboratories Ltd to make it available in 91 developing countries including India. Cadila Healthcare, Mylan Laboratories Ltd, Sequent Scientific Ltd, Strides Arcolab Ltd and Hetero Drugs Ltd are the others who will now be able to make and sell the Sovaldi generic, the company said in a statement.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Hepatitis, Health

Reuters

Gilead licenses hepatitis C drug to Cipla, Ranbaxy, 5 others

U.S. drugmaker Gilead Sciences Inc said on Monday it has licensed its hepatitis C drug to seven companies including Cipla Ltd and Ranbaxy Laboratories Ltd to make it available in 91 developing countries including India. Cadila Healthcare, Mylan Laboratories Ltd, Sequent Scientific Ltd, Strides Arcolab Ltd and Hetero Drugs Ltd are the others who will now be able to make and sell the Sovaldi generic, the company said in a statement.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Hepatitis, Health

Business Wire

Gilead Announces Generic Licensing Agreements to Increase Access to...

Indian companies granted license to produce generic sofosbuvir and investigational single tablet regimen of ledipasvir/sofosbuvir for treatment of chronic hepatitis C -- )--Gilead Sciences, Inc. today announced that the company has signed non-exclusive licensing agreements with seven India-based generic pharmaceutical manufacturers to expand access to its chronic hepatitis C medicines in developing countries. The agreements allow the companies - Cadila Healthcare Ltd., Cipla Ltd., Hetero Labs Ltd., Mylan Laboratories Ltd., Ranbaxy Laboratories Ltd., Sequent Scientific Ltd. and Strides Arcolab Ltd. - to manufacture sofosbuvir and the investigational single tablet regimen of ledipasvir/sofosbuvir for distribution in 91 developing countries.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Hepatitis, Health, Startups, Gilead Sciences, CGI Pharmaceuticals, Food and Drug Administration

Seeking Alpha

Celgene Looks Unstoppable

Since mid-2012, Celgene Corporation stock has tripled. Nonetheless, I submit the shares still represent a highly positive, asymmetric risk-reward proposal.

Comment?

Related Topix: Biotech, Celgene, Medicine, Healthcare Industry, Cancer, Health, Regeneron Pharmaceuticals, Biogen Idec

Sun Sep 14, 2014

PR-inside.com

Market Report, "Gilead Sciences, Inc. (GILD) - Pharmaceuticals &...

Gilead Sciences, Inc. is a research-based biopharmaceutical company. The company undertakes the discovery, development and commercialization of innovative medicines in areas of unmet medical need.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Startups, Gilead Sciences, Marketing, San Mateo County, CA, Foster City, CA

Sat Sep 13, 2014

Reuters

RPT-Gilead to raise price for new hepatitis C drug above $84,000

The next generation version of Gilead Sciences Inc's $84,000 hepatitis C drug, already under fire for its record-breaking costs, is going to be even more expensive. Gregg Alton, Gilead's executive vice president of corporate and medical affairs, declined to give an exact price for the new medicine, the first all-oral treatment for the virus which is expected to launch next month.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Hepatitis, Startups, Gilead Sciences

Fri Sep 12, 2014

The Oregonian

Clash between state, drugmaker heats up as Legislature takes up Hepatitis C cost

The whopping price tag of a promising new drug-- $1,000 a pill -- that could help an estimated 95,000 sick Oregonians has the state and commercial insurers balking at coverage. Gilead Sciences wants to sell more Sovaldi, a new drug hailed as a near-miracle cure for the sometimes-fatal Hepatitis C. But citing the 12-week treatment cost of $84,000 , Oregon officials want to put strict new restrictions on access to the drug, especially for those in earlier stages of the disease.

Comment?

Related Topix: Drugs, Hepatitis, Medicine, Health, Oregon, Biotech, Healthcare Industry, Startups, Gilead Sciences, Oregon Government

•••
•••
•••
•••
•••

Seattle Jobs

•••
•••
•••
•••